Carsten Thiel is viewed as a pioneer and innovator in the world of medicine and he is currently EUSA Pharma’s European President. Over the years, he has been able to impact the lives of thousands of patients who have used the medications that he helped to devel and market. Some of these medications that Carsten Thiel was involved with include Neulasta, Vectibix, Prolia, and Strensiq. His ability to lead these successful launches has garnered him a strong reputation and his expertise is often sought by different companies. When making decisions, he always puts medial ethics first in order to keep the best interest of patients in mind.

While Carsten Thiel may be known for his business acumen, he is also highly educated when it comes to science and has multiple degrees to show from it. While attending primary school, he was known as an excellent student and this continued during his college years at Marburg where he studied Biology before attending the University of Bristol. At the University of Bristol, Carsten Theil spent his time learning organic chemistry and biochemistry. He concluded his education with a Ph.D. in Molecular Biolpgy which was earned at the Mx Planck Institute for Biophysical Chemistry.

After graduating, Carsten Thiel decided to choose the pharmaceutical industry as his career path and he began to climb the corporate ladder after seeing a great deal of success early on. His first job in the pharmaceutical industry was with Hoffman La-Roche where he worked as a Product and Communication. Because of a combination of scientific knowledge, interpersonal skills, and innovative ways of thinking, he was able to flourish in his role at the company and began getting promoted to positions with more responsibility. He understands the importance of marketing and being able to maintain a good reputation with the media and patients.

For details: